- NCIt
- C167265
Loading cancer entity…
Loading cancer entity…
Clinical trials
43 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (4)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03422536 | Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma | completed | Phase 2 | 78 | University of ArizonaOTHER | 1 | Sep 4, 2024 | clinicaltrials |
| NCT00896181 | Phase 2 Sequential and Concurrent Chemoradiation for Advanced Nasopharyngeal Carcinoma (NPC) | completed | Phase 2 | 26 | Stanford UniversityOTHER | 1 | Apr 6, 2021 | clinicaltrials |
| NCT01806675 |
| 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy |
| completed |
| Phase 1 / Phase 2 |
| 25 |
| Sanjiv Sam GambhirOTHER |
| 1 |
| Oct 3, 2019 |
| clinicaltrials |
| NCT02794077 | Cyclophosphamide for Nasopharyngeal Carcinoma | completed | Phase 2 | 56 | The University of Hong KongOTHER | 0 | Oct 2, 2019 | clinicaltrials |
| NCT02339558 | Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer | completed | Phase 2 | 45 | National Cancer Institute (NCI)NIH | 3 | Sep 13, 2019 | clinicaltrials |
| NCT02123511 | Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy | completed | Phase 2 | 34 | Mayo ClinicOTHER | 1 | Apr 30, 2019 | clinicaltrials |
| NCT00408694 | Bevacizumab, Cisplatin, Radiation Therapy, and Fluorouracil in Treating Patients With Stage IIB, Stage III, Stage IVA, or Stage IVB Nasopharyngeal Cancer | completed | Phase 2 | 46 | National Cancer Institute (NCI)NIH | 2 | Jan 30, 2018 | clinicaltrials |
| NCT01256385 | Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy(MAESTRO HN) | completed | Phase 2 | 86 | National Cancer Institute (NCI)NIH | 2 | Mar 27, 2017 | clinicaltrials |
| NCT00454142 | Pazopanib Hydrochloride in Treating Patients With Stage IV or Recurrent Nasopharyngeal Cancer | completed | Phase 2 | 33 | National Cancer Institute (NCI)NIH | 1 | Dec 17, 2015 | clinicaltrials |
| NCT00458978 | Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer | completed | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 1 | May 5, 2015 | clinicaltrials |
| NCT00101348 | Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 66 | National Cancer Institute (NCI)NIH | 1 | Jun 11, 2014 | clinicaltrials |
| NCT00492089 | Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer | completed | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | May 9, 2014 | clinicaltrials |
| NCT01596868 | GP VS TP in the Treatment of Advanced Nasopharyngeal Carcinoma in Northwest China | completed | Phase 2 | 60 | Air Force Military Medical University, ChinaOTHER | 1 | Oct 30, 2013 | clinicaltrials |
Data updated 23 days agoSource updated Sep 4, 2024source: clinicaltrials